Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998284 | 0.89 | LCK (0.57) | SRCPDGFRBYES1EPHB4ABL1 | |
| SCHEMBL5997421 | 0.85 | SRC (0.57) | SRCPDGFRBABL1 | |
| SCHEMBL5998386 | 0.81 | JAK2 (0.59) | SRCPDGFRBYES1EPHB4ABL1 | |
| SCHEMBL14304875 | 0.81 | LCK (0.54) | SRCABL1 | |
| SCHEMBL5996220 | 0.79 | SRC (0.56) | SRCPDGFRBYES1EPHB4ABL1 | |
| SCHEMBL5997079 | 0.78 | LCK (0.44) | SRCABL1 | |
| SCHEMBL5997320 | 0.78 | SRC (0.48) | SRCPDGFRBYES1EPHB4ABL1 | |
| SCHEMBL2496663 | 0.78 | SRC (0.59) | SRCPDGFRBYES1EPHB4ABL1 | |
| SCHEMBL5995311 | 0.77 | SRC (0.54) | SRCPDGFRBYES1EPHB4ABL1 | |
| SCHEMBL5440594 | 0.76 | SIGMAR1 (0.54) | SRCPDGFRBYES1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | SRC 2/4885PDGFRB 97/4885YES1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.